Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Event Details

Filter
UKConference

EASL-AASLD joint meeting on alcoholic liver disease and alcoholic hepatitis

Alcohol related liver disease remains the most important cause of liver disease morbidity and mortality in Europe and North America and is therefore relevant to all hepatologists.

Add this event to your calendar: iCal   Google Calendar

Details

During the EASL-AASLD joint meeting on "Definition, therapeutic advances and clinical endpoints in alcoholic liver disease and alcoholic hepatitis" topics on public health, diagnostic definitions, therapeutic advances and clinical endpoints in alcohol related liver disease and alcoholic hepatitis will be discussed.

Alcohol related liver disease (ALD) is the most prevalent cause of advanced liver disease and liver related mortality in Western countries.
Research in ALD spans a wide spectrum from public health to basic science and despite being the ‘Cinderella’ disease area in hepatology, there have been a number of advances in recent years. We would like to take this opportunity to review with you the emerging data from clinical, translational and basic science studies in ALD. Furthermore, as pharmaceutical company interest in ALD begins to evolve we would encourage you to participate in discussions around the endpoints in clinical trials.

This conference will be a unique occasion to interact with experts and top-researchers, to get new ideas but also to contribute in the field of therapeutic development in ALD and alcoholic hepatitis.
      
Conference objectives:
Attendees will be equipped with the most up-to-date evidence based practice information relevant to patients with alcohol related liver disease
The attendees will be familiar with the most important controversies in the field and how the experts are addressing these issues
The attendees will become aware of the rational behind new endpoints in clinical trials
Debate and set endpoints in clinical trials
Discuss and generate guidelines of best practice in alcohol related liver disease

The organisers: Prof. Philippe Mathurin, Prof. Vijay Shah, Prof. Gyongyi Szabo and Prof. Mark Thursz

Prices

EASL Member (excl. of 20% VAT): EUR 450 Non Member (excl. of 20% VAT): EUR 550 Young Investigator and Nurse - EASL Member (excl. of 20% VAT): EUR 150 Young Investigator and Nurse - Non Member (excl. of 20% VAT): EUR 200 Industry Representative (excl. of 20% VAT): EUR 850 EARLY REGISTRATION - EASL Member (excl. of 20% VAT): EUR 300 EARLY REGISTRATION - Non Member (excl. of 20% VAT): EUR 450 EARLY REGISTRATION - Young Invstigator and Nurse - EASL Member (excl. of 20% VAT): EUR 50 EARLY REGISTRATION - Young Investigator and Nurse - Non Member (excl. of 20% VAT): EUR 100 EARLY REGISTRAATION - Industry Representative Young Investigator and Nurse - ESL Member (excl. of 20% VAT): EUR 750

Contact

EASL Office Congress Organisers
com@easloffice.eu

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.